Portal de Periódicos da CAPES

Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy

2004; Lippincott Williams & Wilkins; Volume: 171; Issue: 3 Linguagem: Inglês

10.1097/01.ju.0000113794.34810.d0

1527-3792

Judd W. Moul, Hongyu Wu, Leon Sun, David G. McLeod, Christopher L. Amling, Timothy F. Donahue, Leo Kusuda, Wade J. Sexton, Keith J. O’Reilly, Javier Hernández, Andrew Chung, Douglas W. Soderdahl,

Hormonal and reproductive studies

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2004Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomyis companion ofEarly Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy JUDD W. MOUL, HONGYU WU, LEON SUN, DAVID G. McLEOD, CHRISTOPHER AMLING, TIMOTHY DONAHUE, LEO KUSUDA, WADE SEXTON, KEITH O'REILLY, JAVIER HERNANDEZ, ANDREW CHUNG, and DOUGLAS SODERDAHL JUDD W. MOULJUDD W. MOUL , HONGYU WUHONGYU WU , LEON SUNLEON SUN , DAVID G. McLEODDAVID G. McLEOD , CHRISTOPHER AMLINGCHRISTOPHER AMLING , TIMOTHY DONAHUETIMOTHY DONAHUE , LEO KUSUDALEO KUSUDA , WADE SEXTONWADE SEXTON , KEITH O'REILLYKEITH O'REILLY , JAVIER HERNANDEZJAVIER HERNANDEZ , ANDREW CHUNGANDREW CHUNG , and DOUGLAS SODERDAHLDOUGLAS SODERDAHL View All Author Informationhttps://doi.org/10.1097/01.ju.0000113794.34810.d0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Hormonal therapy (HT) is the current mainstay of systemic treatment for prostate specific antigen (PSA) only recurrence (PSAR), however, there is virtually no published literature comparing HT to observation in the clinical setting. The goal of this study was to examine the Department of Defense Center for Prostate Disease Research observational database to compare clinical outcomes in men who experienced PSAR after radical prostatectomy by early versus delayed use of HT and by a risk stratified approach. Materials and Methods: Of 5,382 men in the database who underwent primary radical prostatectomy (RP), 4,967 patients were treated in the PSA-era between 1988 and December 2002. Of those patients 1,352 men who had PSAR (PSA after surgery greater than 0.2 ng/ml) and had postoperative followup greater than 6 months were used as the study cohort. These patients were further divided into an early HT group in which patients (355) received HT after PSA only recurrence but before clinical metastasis and a late HT group for patients (997) who received no HT before clinical metastasis or by current followup. The primary end point was the development of clinical metastases. Of the 1,352 patients with PSAR clinical metastases developed in 103 (7.6%). Patients were also stratified by surgical Gleason sum, PSA doubling time and timing of recurrence. Univariate and multivariate Cox proportional hazard models were used to evaluate the effect of early and late HT on clinical outcome. Results: Early HT was associated with delayed clinical metastasis in patients with a pathological Gleason sum greater than 7 or PSA doubling time of 12 months or less (Hazards ratio = 2.12, p = 0.01). However, in the overall cohort early HT did not impact clinical metastases. Race, age at RP and PSA at diagnosis had no effect on metastasis-free survival (p >0.05). Conclusions: The retrospective observational multicenter database analysis demonstrated that early HT administered for PSAR after prior RP was an independent predictor of delayed clinical metastases only for high-risk cases at the current followup. Further study with longer followup and randomized trials are needed to address this important issue. References 1 : Cancer statistics, 2003. CA Cancer J Clin2003; 53: 5. Google Scholar 2 : Treatment options for prostate cancer: part I-stage, grade, PSA, and changes in the 1990's. Am J Manag Care1998; 4: 1031. Google Scholar 3 : Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery2002; 132: 213. Google Scholar 4 : Prostate specific antigen only progression of prostate cancer. J Urol2000; 163: 1632. Link, Google Scholar 5 : PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millenium. Eur Urol2003; 43: 12. Google Scholar 6 : Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol2003; 21: 483. Google Scholar 7 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Google Scholar 8 : Introduction to department of defense Center for Prostate Disease Research (CPDR) multicenter national prostate cancer database with 242,227 records on 11,637 men, and analysis of changes in the PSA-era. Urol Oncol2001; 6: 203. Google Scholar 9 : Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA1997; 277: 1456. Google Scholar 10 : Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol2001; 165: 1146. Link, Google Scholar 11 : Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology2003; 61: 742. Google Scholar 12 : Combined-modality staging for localized adenocarcinoma of the prostate. Oncology2001; 15: 1049. Google Scholar 13 Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol1997; 79: 235. Google Scholar 14 : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet2002; 360: 103. Google Scholar 15 : Immediate vs. delayed hormone treatment for prostate cancer: how safe is androgen deprivation?. BJU Int2000; 86: 220. Google Scholar 16 : Immediate hormonal therapy compared with observation following radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med1999; 341: 1781. Google Scholar 17 Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialists' Collaborative Group. Lancet2000; 355: 1491. Google Scholar 18 : Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology2002; 60: 52. Google Scholar 19 : Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol2002; 168: 429. Link, Google Scholar 20 : Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol1995; 154: 1642. Link, Google Scholar From the Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences (JWM, HW, LS), Department of Urology, National Naval Medical Center (TD), Bethesda, Department of Urology, Malcolm Grow Medical Center, Andrews AFB (AC), Maryland, Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, D. C. (JWM, DGM), Department of Urology, San Diego Naval Medical Center, San Diego, California (CA), Department of Urology, Portsmouth Naval Medical Center, Portsmouth, Virginia (LK), Department of Urology, Wilford Hall Medical Center, Lackland AFB (WS), Urology Service, Department of Surgery, Brooke Army Medical Center, San Antonio (JH), Texas, Urology Service, Department of Surgery, Madigan Army Medical Center, Tacoma, Washington (KO), and Urology Service, Department of Surgery, Eisenhower Army Medical Center, Augusta, Georgia (DS)© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMoradzadeh A, Howard L, Freedland S, Amling C, Aronson W, Cooperberg M, Kane C, Klaassen Z, Terris M and Daskivich T (2020) The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical ProstatectomyUrology Practice, VOL. 8, NO. 2, (238-245), Online publication date: 1-Mar-2021.Ravi P, Karnes R, Rangel L and Pagliaro L (2018) Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical ProstatectomyJournal of Urology, VOL. 200, NO. 5, (1075-1081), Online publication date: 1-Nov-2018.Fu A, Tsai H, Haque R, Yood M, Cassidy-Bushrow A, Van Den Eeden S, Keating N, Smith M, Zhou Y, Aaronson D and Potosky A (2016) Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate CancerJournal of Urology, VOL. 197, NO. 6, (1448-1454), Online publication date: 1-Jun-2017.Ploussard G, Almeras C, Briganti A, Giannarini G, Hennequin C, Ost P, Renard-Penna R, Salin A, Lebret T, Villers A, Soulié M, de la Taille A and Flamand V (2015) Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the LiteratureJournal of Urology, VOL. 194, NO. 4, (983-988), Online publication date: 1-Oct-2015.Liu D, Lehmann H, Frick K and Carter H (2012) Active Surveillance Versus Surgery for Low Risk Prostate Cancer: A Clinical Decision AnalysisJournal of Urology, VOL. 187, NO. 4, (1241-1246), Online publication date: 1-Apr-2012.Boorjian S, Tollefson M, Thompson R, Rangel L, Bergstralh E and Karnes R (2012) Natural History of Biochemical Recurrence After Radical Prostatectomy with Adjuvant Radiation TherapyJournal of Urology, VOL. 188, NO. 5, (1761-1766), Online publication date: 1-Nov-2012.Bañez L, Sun L, van Leenders G, Wheeler T, Bangma C, Freedland S, Ittmann M, Lark A, Madden J, Hartman A, Weiss G and Castaños-Vélez E (2010) Multicenter Clinical Validation of PITX2 Methylation as a Prostate Specific Antigen Recurrence Predictor in Patients With Post-Radical Prostatectomy Prostate CancerJournal of Urology, VOL. 184, NO. 1, (149-156), Online publication date: 1-Jul-2010.Loeb S, Makarov D, Schaeffer E, Humphreys E and Walsh P (2010) Prostate Specific Antigen at the Initial Diagnosis of Metastasis to Bone in Patients After Radical ProstatectomyJournal of Urology, VOL. 184, NO. 1, (157-161), Online publication date: 1-Jul-2010.Sengupta S, Amling C, D'Amico A and Blute M (2008) Prostate Specific Antigen Kinetics in the Management of Prostate CancerJournal of Urology, VOL. 179, NO. 3, (821-826), Online publication date: 1-Mar-2008.Siddiqui S, Boorjian S, Inman B, Bagniewski S, Bergstralh E and Blute M (2008) Timing of Androgen Deprivation Therapy and its Impact on Survival After Radical Prostatectomy: A Matched Cohort StudyJournal of Urology, VOL. 179, NO. 5, (1830-1837), Online publication date: 1-May-2008.Hamilton R, Aronson W, Terris M, Kane C, Presti J, Amling C and Freedland S (2008) Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH DatabaseJournal of Urology, VOL. 179, NO. 5, (1785-1790), Online publication date: 1-May-2008.Freedland S and Moul J (2018) Prostate Specific Antigen Recurrence After Definitive TherapyJournal of Urology, VOL. 177, NO. 6, (1985-1991), Online publication date: 1-Jun-2007.Sengupta S, Blute M, Bagniewski S, Myers R, Bergstralh E, Leibovich B and Zincke H (2018) Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts SurvivalJournal of Urology, VOL. 175, NO. 5, (1684-1690), Online publication date: 1-May-2006.Granfors T, Modig H, Damber J and Tomic R (2018) Long-Term Followup of a Randomized Study of Locally Advanced Prostate Cancer Treated With Combined Orchiectomy and External Radiotherapy Versus Radiotherapy AloneJournal of Urology, VOL. 176, NO. 2, (544-547), Online publication date: 1-Aug-2006.Freedland S, Humphreys E, Mangold L, Eisenberger M and Partin A (2018) Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific MortalityJournal of Urology, VOL. 176, NO. 4, (1404-1408), Online publication date: 1-Oct-2006.Ryan C and Small E (2018) High Risk Biochemical Relapse and the Timing of Androgen Deprivation TherapyJournal of Urology, VOL. 176, NO. 6S, (S61-S65), Online publication date: 1-Dec-2006.VICINI F, VARGAS C, ABNER A, KESTIN L, HORWITZ E and MARTINEZ A (2018) LIMITATIONS IN THE USE OF SERUM PROSTATE SPECIFIC ANTIGEN LEVELS TO MONITOR PATIENTS AFTER TREATMENT FOR PROSTATE CANCERJournal of Urology, VOL. 173, NO. 5, (1456-1462), Online publication date: 1-May-2005.Related articlesJournal of Urology9 Nov 2018Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy Volume 171Issue 3March 2004Page: 1141-1147 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordshormonesrecurrenceprostatectomyprostate-specific antigenprostatic neoplasmsMetricsAuthor Information JUDD W. MOUL Financial interest and/or other relationship with Astra Zeneca, TAP and Aventis. More articles by this author HONGYU WU Nothing to disclose. More articles by this author LEON SUN Nothing to disclose. More articles by this author DAVID G. McLEOD Nothing to disclose. More articles by this author CHRISTOPHER AMLING Financial interest and/or other relationship with TAP and Astra Zeneca. More articles by this author TIMOTHY DONAHUE Nothing to disclose. More articles by this author LEO KUSUDA Nothing to disclose. More articles by this author WADE SEXTON Nothing to disclose. More articles by this author KEITH O'REILLY Nothing to disclose. More articles by this author JAVIER HERNANDEZ Financial interest and/or other relationship with TAP. More articles by this author ANDREW CHUNG Financial interest and/or other relationship with TAP and Astra Zeneca. More articles by this author DOUGLAS SODERDAHL Financial interest and/or other relationship with TAP and Astra Zeneca. More articles by this author Expand All Advertisement PDF downloadLoading ...